Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Background: Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6, has demonstrated synergistic anticancer activity with paclitaxel in multiple solid tumor models. Combination therapy using citarinostat with paclitaxel was evaluated...

Full description

Bibliographic Details
Main Authors: Connarn, J.N (Author), Dumitru, C.D (Author), Gordon, M.S (Author), Harvey, R.D (Author), Juric, D. (Author), Le Bruchec, Y. (Author), Lu, B. (Author), Sarantopoulos, J. (Author), Shapiro, G.I (Author), Zarotiadou, A. (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
adult
advanced solid tumors
alanine aminotransferase
anemia
antineoplastic activity
Article
aspartate aminotransferase
breast cancer
citarinostat
clinical article
clinical trial
combination therapy
computer assisted tomography
controlled study
dehydration
demography
drug dose escalation
epigenetics
female
follow up
HDAC inhibition
histology
histone acetylation
histone deacetylase
human
human tissue
hypophosphatemia
lung cancer
male
maximum tolerated dose
middle aged
multiple cycle treatment
neurotoxicity
neutropenia
nuclear magnetic resonance imaging
ovary tumor
paclitaxel
pharmacodynamics
pharmacokinetics
solid malignant neoplasm
taxane derivative
thrombocytopenia
urinary tract infection
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items